


PHARMACEUTICAL 2017

GT Biopharma Inc. Rank 246 of 292





PHARMACEUTICAL 2017

GT Biopharma Inc. Rank 246 of 292

The relative strengths and weaknesses of GT Biopharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of GT Biopharma Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 371% points. The greatest weakness of GT Biopharma Inc. is the variable Liabilities, Current, reducing the Economic Capital Ratio by 503% points.

The company's Economic Capital Ratio, given in the ranking table, is -121%, being 124% points below the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	21
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	18,949
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	30,407
Other Revenues	0
Property and Equipment	4.0
Research and Development	975
Selling, General and Administrative Expense	8,399

Output Variable	Value in 1000 USD
Assets	25
Liabilities	18,949
Expenses	9,374
Revenues	0
Stockholders Equity	-18,924
Net Income	21,033
Comprehensive Net Income	21,033
Economic Capital Ratio	-121%

